MO2-1-6Adoption of multigene panel testing for hereditary cancer CancerNext in Tohoku University Hospital

Abstract Recent developments of cancer genomic medicine increase importance of diagnosis and treatment of hereditary cancer syndrome. Currently, for diagnosis of hereditary cancer, we often perform sequencing analysis for single or couple of genes after screening by clinical diagnosis. As a result, some individuals with segregation of cancer in their families harbor no pathological mutations, while, other individuals without obvious segregation of cancer in their families harbor germline mutations. Therefore, only single gene analysis or clinical information including family history is insufficient to identify some proportion of hereditary cancer individuals. Genetic tests that can comprehensively analyze multiple genes enable us to diagnose hereditary cancer more efficiently and to improve treatment strategies more effectively. In Tohoku University Hospital, a multi-gene panel testing for hereditary cancer "CancerNext" developed by Ambry Genetics Inc. have been adopted since March 1, 2019. This test covers 34 genes associated with increased risks for at least one of 8 major cancers (breast cancer, ovarian cancer, colorectal cancer, uterine cancer, pancreatic cancer, prostate cancer, gastric cancer and melanoma). We have already performed somatic multi-gene panel testing for cancer as Designated Core Hospitals for Cancer Genomic Medicine. Results of the "CancerNext" test are provided to the individuals after the discussion by tumor molecular board. We will report the actual situation of proceeding the test and the test result of five patients or more.